- Home
- IMNM vs NOG Comparison
IMNM vs NOG Comparison
Compare IMNM & NOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNM | NOG |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | IMNM | NOG |
|---|---|---|
| Price | $22.03 | $22.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $32.80 | $31.14 |
| AVG Volume (30 Days) | 915.1K | ★ 2.5M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 6.44% |
| EPS Growth | ★ 51.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,941,000.00 | ★ $2,475,723,000.00 |
| Revenue This Year | N/A | $14.07 |
| Revenue Next Year | $1,127.34 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.23 |
| 52 Week Low | $7.96 | $20.18 |
| 52 Week High | $27.65 | $32.62 |
Technical Indicators
Market Signals| Indicator | IMNM | NOG |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 34.19 |
| Support Level | $19.23 | $20.74 |
| Resistance Level | $23.24 | $22.86 |
| Average True Range (ATR) | 1.27 | 0.78 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 55.07 | 0.17 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).